A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation.

Trial Profile

A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Fludarabine (Primary) ; Melphalan (Primary) ; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Bone marrow disorders; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Immunological disorders; Lymphoid leukaemia; Lymphoproliferative disorders; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 17 Mar 2015 Planned End Date changed from 1 Feb 2013 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Actual initiation date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 26 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top